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Plasma leptin is partly cleared by the kidney and is elevated in
hemodialysis patients. Leptin, the gene product of the ob gene, is
important in the control of appetite in rodents and may have an important
role in humans. The clearance of leptin from the circulation is unknown.
As the leptin receptor is present in the kidney, we evaluated the role of the
kidney in removing circulating leptin in humans. We measured leptin in
aortic and renal vein plasma in 8 patients with intact renal function and 6
patients with impaired renal function who were undergoing elective
cardiac catheterization. Renal blood flow was measured in all patients to
calculate net mass balance across the kidney. In patients with intact renal
function there is net renal uptake of 12% of circulating leptin, whereas in
patients with renal insufficiency there is no renal uptake of leptin. In a
separate cohort of 36 patients with end-stage renal failure on hemodial-
ysis, peripheral leptin levels factored for body mass index was increased
by > fourfold as compared to a group of healthy controls (N = 338). In
addition, plasma leptin is not cleared by hemodialysis with a modified
cellulose membrane. Additional studies are required to evaluate the role
of leptin in mediating the anorexia of uremia.
Leptin is a 16 kDa plasma protein that is encoded by the ob
gene [1], secreted by adipocytes [1, 21, and serves an important
role in suppressing appetite in mice [3—5]. It is postulated that as
adipocytes increase in size with increased food intake, there is
increased leptin binding to receptors in the hypothalamus that
inhibits further food intake [6]. The mRNA for the receptor for
leptin has been localized to the hypothalamus, choroid plexus,
lung and kidney [7]. Spontaneous mutation of the leptin receptor
predictably results in a leptin-resistant obese phenotype (db/db
mouse) [8, 9].
The role of leptin in controlling food intake in humans is not
clear; however, a substantial amount of data suggest that it is
likely important. Leptin levels in peripheral blood of humans
appear to undergo a circadian pattern [10]. In relation to the
8 a.m. fasting level, there is a decrease of 20% during mid-day and
a rise to about 120% during the nocturnal hours. This may serve
to stimulate appetite during mid-day and suppress appetite during
the sleeping hours. Leptin levels in humans have a positive
correlation with indices of body fat, and are elevated in obese
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patients [2, 11]. It has been recently noted that abdominal fat
secretion of leptin into the circulation correlates with the amount
of abdominal fat, as demonstrated by measuring arterio-venous
differences across percutaneous abdominal fat [12]. The half-life
of leptin was estimated to be about 25 minutes in this study [12].
Serum leptin has been recently noted to exist in a bound and free
form. The percentage of bound leptin is on the order of 46% in
non-obese individuals and < 20% in obese individuals (M. Sinha,
manuscript in press). These observations demonstrate that obese
patients have elevated levels of free leptin and thus an underlying
defect in leptin signaling may lead to resistance of the action of
leptin and consequent obesity. Although no defects have thus far
been identified in the leptin receptor from the hypothalamus in
obese humans, post-receptor signaling defects may underlie leptin
resistance [13].
Given the short half-life of leptin in the circulation and the
presence of the leptin receptor in the kidney, we postulated that
the kidney serves as a site of clearance of leptin from the
circulation. Other polypeptides of similar size (6 to 20 kDa), such
as insulin [14—16], parathyroid hormone, and growth hormone are
recognized to be filtered at the glomerulus and taken up and
degraded by proximal tubular cells [14, 17]. If leptin is cleared by
the kidney we would expect to see a net uptake of leptin across the
renal vascular bed and decreased renal uptake in patients with
renal insufficiency. Furthermore, leptin levels would be expected
to be elevated in chronic hemodialysis patients. Elevated leptin
levels may then have an important influence on the decreased
appetite that is characteristic of patients with end-stage renal
disease.
In the present study, we measured levels of leptin in aortic and
renal vein plasma from patients with varying degrees of renal
function, who were undergoing elective cardiac catheterization.
Leptin levels were also measured in pre- and post-hemodialysis
peripheral arterial plasma from a separate cohort of chronic
hemodialysis patients. We report here that circulating leptin is
extracted by the kidney and that net extraction is reduced with
renal insufficiency. Leptin levels are elevated fourfold in end-stage
renal failure patients and hemodialysis with modified cellulose
membranes does not remove circulating leptin. The elevation of
plasma leptin in dialysis patients is due almost entirely to in-
creased free leptin and not to an increased fraction of bound
leptin.
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Methods
Study subjects
Male and female patients who were scheduled for elective
cardiac catheterization by their cardiologist were eligible for
enrollment in this protocol at the Cooper Hospital/University
Medical Center (Camden, NJ, USA). Exclusion criteria for our
studies included New York Heart Association Class IV congestive
heart failure, a recent myocardial infarction, pregnancy, unstable
renal function, or "medical instability" as judged by the cardiol-
ogist. The patients were enrolled in the study on a consecutive
basis if they met the study criteria. All patients had complete
blood count, plasma glucose and serum creatinine concentrations
determined before catheterization.
A separate cohort of patients were randomly selected from the
outpatient hemodialysis unit of Thomas Jefferson University
Hospital. All patients from two separate dialysis shifts underwent
pre- and post-hemodialysis blood sampling from the arterial limb
of their vascular access. Patients on corticosteroid therapy were
excluded from the study due to a possible interaction of cortico-
steroids with leptin production [18]. The dialysis filter used in all
these patients was composed of modified cellulose (Hemophane)
with a pore size of 11,000 daltons. Informed consent was obtained
from all patients, and the research protocols were reviewed and
approved by the Institutional Review Committee at Cooper
Hospital/University Medical Center and Thomas Jefferson Uni-
versity, respectively.
Plasma collection and measurement of renal blood flow
After routine right-sided cardiac catheterization was com-
pleted, a 7 French dual thermistor catheter (Webster Laborato-
ries, Baldwin Park, CA, USA) was passed through the femoral
vein sheath and fluoroscopically guided into the left renal vein
(without contrast) for measurement of renal blood flow (RBF)
and renal vein blood sampling. The position was confirmed by
determination of the oxygen saturation of the blood withdrawn
from the catheter. A saturation significantly greater than that of
the pulmonary artery and roughly 10 to 15% lower than aortic
saturation is compatible with placement in the renal vein [19, 20].
The femoral arterial catheter that was to be used for ventriculog-
raphy was also used to obtain aortic specimens in the vicinity of
the renal artery while en-route to its position in the left ventricle.
Samples of plasma were stored at —70°C until assayed. RBF was
measured by a continuous thermodilution technique as described
previously [191. For each determination of RBF, 5% dextrose was
infused with an automated injector at a constant rate of 50 mI/mm
until the resistance deflections of both thermistors consequent to
the thermodilution temperature changes were stable. The mea-
surement of RBF was performed in triplicate. Our replicate
measurements have a mean coefficient of variation of 7.8% [19].
Determination of body fat mass
Body fat mass was determined in six patients with BMI > 30
kg/rn2 using bioelectric impedance performed on two separate
occasions two weeks apart at the end of hemodialysis sessions.
The test was performed using LJL Bioelectrical Impedance
Analysis 1O1Q following a previously published protocol [21]. The
test was performed by the Thomas Jefferson University Hospital
nutritionists (S.E. and M.E.F.) who routinely perform these tests
in our dialysis population. This test has been validated to correlate
very well with measurements from dual energy X-ray absorptiorn-
etry in chronic hemodialysis patients [22].
Radioimmunoassay for leptin
Plasma leptin levels were determined by RIA as previously
described [21. Antihurnan leptin antiserum was raised in rabbits
immunized with recombinant leptin [23]. No cross reactivity was
evident in leptin RIA for human insulin, glucagon, and IGF-1 up
to 10 jkg/ml concentrations. The leptin was radiolabeled with
iodine 125 by the Bolton-Hunter method [24] and purified by gel
filtration using Sephadex G-25 (Pharmacia Biotech, Piscataway,
NJ, USA). In the leptin radioimrnunoassay, recombinant leptin in
charcoal treated plasma or test plasma (in duplicate) was incu-
bated in phosphate buffered saline (pH 7.4) containing 0.1%
Triton-X-100 with antileptin serum (at a dilution of 1:2000) for 16
hours at 4°C in a total volume of 400 jtl. '251-labeled leptin (30,000
counts per minute in 100 d) was then added, and the incubation
continued for an additional 24 hours. Antiserum-bound 125j
labeled leptin was precipitated by the addition of 100 pA of sheep
antirabbit IgG serum (Antibodies Inc., Davis, CA, USA), 100 pA
of normal rabbit serum (GIBCO BRL, Gaithersburg, MD, USA),
and 100 pl of 10% polyethylene glycol. The tubes were centri-
fuged for 15 minutes at 2200 rpm, after which the supernatant was
decanted and the pellet counted in a Packard 5000 gamma
counter (Packard, Downers Grove, IL, USA). The limit of
detection was 0.5 ng/ml, the intraassay standard coefficient of
variation was 8.3%, and the interassay coefficient of variation was
6.2% at a standard concentration of 4.9 ng/ml. With higher values
the coefficient of variations for intrassay and interassay measure-
ments are lower.
Measurement of bound and free leptin
Measurements to separate bound and free forms of leptin were
performed as previously described (27). Plasma samples were
fractionated by Sephadex G-100 gel filtration. Fractions eluting
between void and bed volumes were assayed for immunoreactive
leptin. Percent bound and % free leptin eluting in two peaks were
calculated by dividing with total leptin eluted. Absolute levels of
bound and free leptin were then calculated by multiplying %
bound and % free leptin with total leptin concentrations and
dividing by 100.
Calculations and statistical analysis
The leptin mass in the aortic and renal vein plasma, respec-
tively, were calculated by the following formulae:
Renal arterial leptin mass (nglmin) =
Renalvein leptin mass (nglmin) =
Aortic leptin (nglml) X RBF (mi/mm)
Renal vein leptin (ng/ml) >< RBF (mI/mm)
Net renal extraction was defined as:
Net renal extraction (ng/min) =
Renal arterial leptin mass (ng/min) — Renalvein leptin mass (ng/min)
A positive value was interpreted as renal extraction of leptin
from the circulation.
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Table 1. Clinical characteristics of patients undergoing renal vein
catheterization
NM/F 13/I
Age years 60 (49—78)
BMI kg/rn2 26.9 (22. 1—47.0)
Serum creatinine mg/dl 1.1 (0.7—3.6)
Renal blood flow mI/mm 428 (70—1056)
Data are presented as median and (range).
Aortic Renal venous
Leptin concentration ng/rnl 7.34 0.95 6.95 0.9
Leptin mass ng/rnin 3340 651 3065 571
Leptin concentration ng/ml in 7.91 1.4 7.02 1.3
patients with creatinine
<1.4 mg/dl
Leptin mass ng/min in patients 4241 895 3761 807
with creatinine < 1.4 mgldl
Leptin concentration in 6.57 1.18 6.85 1.37
patients with creatinine
> 1.4 mg/dl
Leptin mass in patients with 2138 753 2137 675
creatinine > 1.4 mgldl
For comparing differences between arterial and venous levels
and for pre- and post-hemodialysis samples within patients, paired
t-test was used (two-tailed). Linear correlations were assessed
with Spearman's rank correlation. Simple linear regression anal-
yses were performed on variables which demonstrated significant
correlation (P < 0.05). The analyses were performed with SAS
software.
Results
Renal extraction of circulating leptin
Clinical characteristics of the patients from whom aortic and
renal vein plasma samples were obtained are presented in Table
1. The majority of the patients were male and over the age of 50
years. Seven of 14 patients were classified as obese with BMI >
27.8 kg/m2. Of the 14 patients evaluated, 8 had a serum creatinine
below 1.4 mg!dl (123.8 j.rmol/liter), indicating relatively normal
renal function whereas 6 patients had a serum creatinine mea-
surement between 1.4 mg/dl and 3.6 mg/dI (123.8 to 318.2
jtmol/litcr), indicating mild to moderate renal insufficiency.
Leptin levels across the renal bed are noted in Table 2. There
is an insignificant decrease of leptin concentration and mass
values in the renal venous samples as compared to the aortic
samples in the entire cohort. However, in patients with serum
creatinine below 1.4 mg/dl (123.8 jrmol/liter; N = 8) there is a
significant decrease of 12.1% 2.4% of plasma leptin levels upon
leaving the kidney. In patients with mild to moderate renal
insufficiency (N = 6) there was no renal extraction of leptin.
Leptin levels in urine were below the sensitivity of our assay. The
net values of leptin across the renal bed expressed as mass/minute
was negatively correlated with the serum creatinine among all
patients evaluated (P = 0.004, r =
—0.741). Linear regression
analysis of net leptin mass expressed as the dependent variable
and the serum creatinine as the independent variable (Fig. 1)
demonstrates a highly significant inverse relationship and an r2
value of 0.561. Thus, about 50% of the net renal extraction of
leptin is determined by the degree of renal function, as measured
by the serum creatinine. The lower mean leptin mass values in the
arterial and venous samples in patients with renal impairment
(Table 2) is largely due to the lower mean renal blood flow in this
group (363 146 ml/min) as compared to the mean renal blood
flow in patients with intact renal function (562 87 ml/min).
Elevated leptin levels in patients on hemodialysis
The clinical characteristics of the 36 patients undergoing
chronic hemodialysis are presented in Table 3. All patients had
been on dialysis for over six months and had no intercurrent
infections. The mean leptin level among all the dialysis patients
evaluated was 37.6 10.6 ng/ml (Fig. 2A), which was 4.5-fold
greater (P < 0.01) than the mean leptin level among 338
volunteers with normal renal function (8.25 7.25 ng/ml), despite
a mean lower BMI in the dialysis patients (24.7 0.9 vs. 27.8
0.3 kg/rn2, respectively, P < 0.005). When leptin level was factored
for the BMI of individual patients (Fig. 2B) the dialysis patients
had a mean ratio of 1.30 0.32, whereas the normal renal
function group had a ratio of 0.29 0.01 (P < 0.005). Leptin
levels exhibited a positive correlation with BMI in the dialysis
patients (r = 0.615, P < 0.001; Fig. 3).
Leptin levels were also evaluated pre- and post-dialysis to
evaluate if leptin may be cleared during hemodialysis. The dialysis
membranes used in all patients was a modified cellulose mem-
brane (Hemophane) with a pore size of 11,000 daltons. As would
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Fig. 1. Analysis of net leptin mass across the renal bed versus serum
crearinine (r = 0.771; P = 0.001).
TabJe 3. Clinical characteristics of patients on chronic hemodialysis
NM/F 15/21
Age years (range) 60.3 (3 1—80)
BMI kg/rn2 (range) 24.65 (15—37.8)
Diabetes mellitus yes/no 12/24
Data arc presented as mean standard error.
P < 0.005 compared with aortic values
0 1 2 3
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Fig. 3. Analysis of leptin levels versus BMI of patients on chronic hemodi-
alysis (r = 0.615; P 0.001).
he predicted by the molecular weight of leptin (14 to 16,000
daltons), there was no evidence of clearance across the dialysis
membrane with the post-dialysis levels significantly greater than
pre-dialysis levels (45.1 13.6 vs. 37.7 10.6 ng/ml, respectively,
paired 1-test, P < 0.05; Fig. 4). Of the 36 patients evaluated, 31
patients had higher post-dialysis levels as compared to their
pre-dialysis level.
Among the 7 dialysis patients with BMI greater than 30 kg/rn2,
3 patients were found to exhibit extraordinarily high values (>200
ng/ml) whereas 4 patients did not (Table 4). This difference was
not due to a difference in body fat stores as determined by
bioimpedance analysis in these patients. As leptin exists in a free
and bound form and patients with renal failure often have altered
protein binding, we evaluated the free and bound form in the
three patients with leptin levels > 200 ng/ml. A representative
elution profile of one of the three patients is shown in Figure 5,
the percentage of free leptin was greater than 95% of the total
leptin. The percent of total leptin in the free form was 95.1% and
Patient # BMI kg/rn2 Body fat mass % Leptinng/rnl
4 30 34 9.2
7 35.6 26 33.0
15 37.8 50 87.9
21 30 42 50.2
11 31.9 45 250.0
17 36.5 n/aa 212.0
35 31.4 27 241.0
Patient refused
97.5% in the remaining two patients. The distribution of free and
bound leptin is similar to findings in similarly obese patients with
normal renal function (27).
Discussion
Leptin is secreted by adipocytes into the circulation and pre-
sumably binds to leptin receptors in the brain to suppress appetite.
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Fig. 2. A. Mean leptin levels in normal
volunteers and in patients on chronic
hemodialysis. B. Mean leptin levels standardized
for BMI in normal volunteers and in patients
on chronic hernodialysis. Data are mean SE.
P < 0.01 compared with normal volunteers.
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Fig. 4. Mean leptin levels from pre-hernodialysis and post-hemodialysis
samples (P < 0.05).
Table 4. Plasma leptin concentration in seven dialysis patients with
BMI greater than 30 kg/rn2
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Fig. 5. Representative sephadex G-100 elution profile of immunoreactive
leptin in plasma from patient #17. Peak I represents bound leptin. Peak II
represents free leptin.
The short half-life of free leptin requires that it be rapidly cleared
from the blood either via degradation in peripheral tissues or via
filtration across the glomerular basement membrane into the
urinary space. Given that the kidney is one of several peripheral
tissues that exhibit the leptin receptor and the size of leptin allows
it to cross the glomerular capillary basement membrane, we
hypothesized that the kidney may be a major organ accounting for
removal of leptin from the circulation. Our study demonstrates
that there is net renal extraction of leptiri in patients with normal
renal function, whereas this renal extraction is impaired in
patients with mild to moderate renal insufficiency.
Determination of the contribution of clearance by glomerular
filtration versus basolateral tubular uptake of leptin remains to be
evaluated. Based on studies with insulin, both processes may
occur to clear insulin from the circulation [14, 171. It is unclear
what role the leptin receptor would have in the kidney apart from
a clearance role. Localization studies of the leptin receptor, and
analysis of the leptin receptor mRNA and protein from kidney
tissue will help to determine its functional role.
Similar to insulin levels, which are elevated in patients with
advanced kidney disease [17], leptin levels were found to be
markedly elevated in patients with end-stage renal failure. Al-
though leptin levels are positively correlated with BMI in the
dialysis patients, as in patients with normal renal function, the
levels are four times as high when factored for BMI. The elevated
leptin levels are likely due to the inability of the kidney to clear
circulating leptin. Whether nonrenal tissues, that is, lung or liver,
may play a role in clearance of leptin is unknown. In addition, it
appears that the presence of high amounts of leptin in the
circulation does not markedly affect the ability of the adipocyte to
produce more leptin. This is based on the observation that leptin
levels remain significantly correlated with the BMI despite the
inordinately high levels. This observation confirms in vitro findings
that exogenous leptin does not regulate adipocyte production of
leptin [251.
Circulating leptin is not removed by the modified cellulose
dialysis membranes used in our patients, presumably due to the
pore size of the membranes. In fact, leptin levels are higher
post-dialysis than pre-dialysis. This observation is likely a reflec-
tion of ultrafiltration of fluid from the vascular space across the
dialysis membrane. It would be of enormous interest to evaluate
if high flux, large permeability dialysis membranes are able to
clear or absorb leptin, and also if peritoneal dialysis clears leptin
across the peritoneum.
Elevated leptin levels in hemodialysis patients appears largely
due to an increase of the free form of leptin, as demonstrated by
our analysis of free and bound leptin in the three patients with the
highest levels. It is not clear why several patients have markedly
high levels of leptin out of proportion to their BMI. Although our
results on a limited number of patients suggest that markedly high
levels of leptin (> 200 nglml) is not simply a result of enhanced
body fat stores, this issue needs further examination in future
studies. These patients were not taking corticosteroids nor on
agents that might pharmacologically inhibit cAMP production.
Corticosteroids have been found to stimulate leptin production
and agents that raise intracellular cAMP levels inhibit leptin
production [18]. A recent study demonstrated that endotoxin
induces expression of leptin mRNA and protein in hamsters [26].
It is conceivable that hemodialysis patients are exposed to chronic
low levels of endotoxin during the hemodialysis procedure which
may contribute to elevated leptin production. In the 3 patients
with leptin levels > 200 nglml, there was no evidence of overt
infection preceding or following the date of leptin measurements.
In summary, the kidney contributes to clearance of circulating
leptin in humans. Patients on hemodialysis have increased levels
of circulating free leptin and hemodialysis with cuprophane-based
dialysis membranes does not remove circulating leptin. Further
studies are required to evaluate the significance of these elevated
leptin levels in relation to indices of appetite in patients with
end-stage renal failure.
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Note added in proof
A recently published study in rats demonstrated that the kidney cleared
30% of circulating I125-leptin. Cumin F, Baum H, Levens N: Leptin is
cleared from the circulation primarily by the kidney. mt J Obesity
20:1120—1126, 1996.
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